TrialAnnals of oncology : official journal of the European Society for Medical Oncology2022

FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.

V Subbiah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.